Ruxolitinib – November 2022

• Brand names:
  • Jakavi®
• Pharmaceutical Company:
  • Novartis Pharmaceuticals Australia Pty Limited
• Condition/Indication: Chronic Graft vs Host Disease
• Meeting Date: November 2022
• Public Summary Document (PSD) July 2022 September 2022 November 2022 PBAC Meetings - (PDF 967KB)
• Public Summary Document (PSD) July 2022 September 2022 November 2022 PBAC Meetings - (Word 384KB)

Related Public Summary Documents

• Ruxolitinib – July 2022